PMC:7408073 / 13827-15276
Annnotations
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T94 | 1008-1012 | Body_part | denotes | cell | http://purl.org/sig/ont/fma/fma68646 |
T95 | 1064-1068 | Body_part | denotes | lung | http://purl.org/sig/ont/fma/fma7195 |
LitCovid-PD-UBERON
Id | Subject | Object | Predicate | Lexical cue | uberon_id |
---|---|---|---|---|---|
T22 | 91-115 | Body_part | denotes | renin-angiotensin system | http://purl.obolibrary.org/obo/UBERON_0018229 |
T23 | 117-120 | Body_part | denotes | RAS | http://purl.obolibrary.org/obo/UBERON_0018229 |
T24 | 1064-1068 | Body_part | denotes | lung | http://purl.obolibrary.org/obo/UBERON_0002048 |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
497 | 0-3 | Gene | denotes | ACE | Gene:59272 |
498 | 8-12 | Gene | denotes | ACE2 | Gene:59272 |
499 | 123-127 | Gene | denotes | ACE2 | Gene:59272 |
500 | 273-283 | Gene | denotes | bradykinin | Gene:3827 |
501 | 300-311 | Gene | denotes | B1 receptor | Gene:623 |
502 | 338-346 | Gene | denotes | Ang (1–9 | Gene:284 |
503 | 382-415 | Gene | denotes | ACE/Ang II/Ang II type 1 receptor | Gene:1636 |
504 | 417-421 | Gene | denotes | AT1R | Gene:185 |
505 | 594-615 | Gene | denotes | nitric oxide synthase | Gene:4843 |
506 | 857-860 | Gene | denotes | ACE | Gene:59272 |
507 | 876-880 | Gene | denotes | ACE2 | Gene:59272 |
508 | 921-925 | Gene | denotes | AT1R | Gene:185 |
509 | 1151-1155 | Gene | denotes | ACE2 | Gene:59272 |
510 | 1314-1318 | Gene | denotes | ACE2 | Gene:59272 |
511 | 1282-1285 | Gene | denotes | ACE | Gene:59272 |
512 | 324-332 | Gene | denotes | Ang (1–7 | Gene:284 |
513 | 184-192 | Gene | denotes | Ang (1–7 | Gene:284 |
514 | 539-542 | Gene | denotes | AT2 | Gene:186 |
515 | 914-920 | Gene | denotes | Ang II | Gene:24179 |
516 | 971-982 | Chemical | denotes | aldosterone | MESH:D000450 |
517 | 469-480 | Disease | denotes | hypotension | MESH:D007022 |
518 | 814-825 | Disease | denotes | dysfunction | MESH:D009461 |
519 | 984-996 | Disease | denotes | inflammation | MESH:D007249 |
520 | 1028-1038 | Disease | denotes | thrombosis | MESH:D013927 |
521 | 1040-1059 | Disease | denotes | cardiac dysfunction | MESH:D006331 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T121 | 469-480 | Disease | denotes | hypotension | http://purl.obolibrary.org/obo/MONDO_0005468 |
T122 | 984-996 | Disease | denotes | inflammation | http://purl.obolibrary.org/obo/MONDO_0021166 |
T123 | 1028-1038 | Disease | denotes | thrombosis | http://purl.obolibrary.org/obo/MONDO_0000831 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T149 | 221-224 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
T150 | 237-244 | http://purl.obolibrary.org/obo/PR_000018263 | denotes | peptide |
T151 | 312-322 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activation |
T152 | 348-356 | http://purl.obolibrary.org/obo/PR_000018263 | denotes | peptides |
T153 | 630-640 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activation |
T154 | 707-708 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T155 | 812-813 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T156 | 934-944 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activation |
T157 | 1008-1012 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cell |
T158 | 1064-1068 | http://purl.obolibrary.org/obo/UBERON_0002048 | denotes | lung |
T159 | 1064-1068 | http://www.ebi.ac.uk/efo/EFO_0000934 | denotes | lung |
T160 | 1156-1164 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activity |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T74 | 21-25 | Chemical | denotes | zinc | http://purl.obolibrary.org/obo/CHEBI_27363|http://purl.obolibrary.org/obo/CHEBI_30185 |
T76 | 97-108 | Chemical | denotes | angiotensin | http://purl.obolibrary.org/obo/CHEBI_48433 |
T77 | 117-120 | Chemical | denotes | RAS | http://purl.obolibrary.org/obo/CHEBI_63620 |
T78 | 138-149 | Chemical | denotes | angiotensin | http://purl.obolibrary.org/obo/CHEBI_48433 |
T79 | 151-154 | Chemical | denotes | Ang | http://purl.obolibrary.org/obo/CHEBI_48433 |
T80 | 162-164 | Chemical | denotes | II | http://purl.obolibrary.org/obo/CHEBI_74067 |
T81 | 170-173 | Chemical | denotes | Ang | http://purl.obolibrary.org/obo/CHEBI_48433 |
T82 | 184-187 | Chemical | denotes | Ang | http://purl.obolibrary.org/obo/CHEBI_48433 |
T83 | 237-244 | Chemical | denotes | peptide | http://purl.obolibrary.org/obo/CHEBI_16670 |
T84 | 266-269 | Chemical | denotes | Arg | http://purl.obolibrary.org/obo/CHEBI_16467|http://purl.obolibrary.org/obo/CHEBI_29952 |
T86 | 273-283 | Chemical | denotes | bradykinin | http://purl.obolibrary.org/obo/CHEBI_3165 |
T87 | 324-327 | Chemical | denotes | Ang | http://purl.obolibrary.org/obo/CHEBI_48433 |
T88 | 338-341 | Chemical | denotes | Ang | http://purl.obolibrary.org/obo/CHEBI_48433 |
T89 | 348-356 | Chemical | denotes | peptides | http://purl.obolibrary.org/obo/CHEBI_16670 |
T90 | 386-389 | Chemical | denotes | Ang | http://purl.obolibrary.org/obo/CHEBI_48433 |
T91 | 390-392 | Chemical | denotes | II | http://purl.obolibrary.org/obo/CHEBI_74067 |
T92 | 393-396 | Chemical | denotes | Ang | http://purl.obolibrary.org/obo/CHEBI_48433 |
T93 | 397-399 | Chemical | denotes | II | http://purl.obolibrary.org/obo/CHEBI_74067 |
T94 | 594-606 | Chemical | denotes | nitric oxide | http://purl.obolibrary.org/obo/CHEBI_16480 |
T95 | 601-606 | Chemical | denotes | oxide | http://purl.obolibrary.org/obo/CHEBI_25741|http://purl.obolibrary.org/obo/CHEBI_29356 |
T97 | 914-917 | Chemical | denotes | Ang | http://purl.obolibrary.org/obo/CHEBI_48433 |
T98 | 918-920 | Chemical | denotes | II | http://purl.obolibrary.org/obo/CHEBI_74067 |
T99 | 971-982 | Chemical | denotes | aldosterone | http://purl.obolibrary.org/obo/CHEBI_27584|http://purl.obolibrary.org/obo/CHEBI_30834 |
T101 | 1269-1279 | Chemical | denotes | antagonist | http://purl.obolibrary.org/obo/CHEBI_48706 |
LitCovid-PD-GO-BP
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T13 | 453-467 | http://purl.obolibrary.org/obo/GO_0042311 | denotes | vasodilatative |
T14 | 953-969 | http://purl.obolibrary.org/obo/GO_0042310 | denotes | vasoconstriction |
T15 | 984-996 | http://purl.obolibrary.org/obo/GO_0006954 | denotes | inflammation |
T16 | 1008-1026 | http://purl.obolibrary.org/obo/GO_0008283 | denotes | cell proliferation |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T68 | 0-122 | Sentence | denotes | ACE and ACE2 are two zinc metalloproteases involved in the biogenesis of the components of renin-angiotensin system (RAS). |
T69 | 123-323 | Sentence | denotes | ACE2 processes angiotensin (Ang) I and II into Ang (1–9) and Ang (1–7), respectively, and it also has other known peptide targets, such as des-Arg(9)-bradykinin, which mediates B1 receptor activation. |
T70 | 324-670 | Sentence | denotes | Ang (1–7) and Ang (1–9) peptides, opposing the effects of ACE/Ang II/Ang II type 1 receptor (AT1R) pathway, are known to mediate vasodilatative (hypotension), antiproliferative and apoptotic effects through Mas and AT2 receptors, respectively, both involving downstream nitric oxide synthase (NOS) pathway activation [38,39,40,41,42,43,44,45,46]. |
T71 | 671-826 | Sentence | denotes | Physiology teaches us that there is a range of normality for every biological parameter, below (defect) and above (excess) of which there is a dysfunction. |
T72 | 827-881 | Sentence | denotes | This is likely to be true for ACE as well as for ACE2. |
T73 | 882-1096 | Sentence | denotes | It is well known that excessive Ang II/AT1R pathway activation induces vasoconstriction, aldosterone, inflammation, excessive cell proliferation, thrombosis, cardiac dysfunction and lung alterations (see Figure 1). |
T74 | 1097-1389 | Sentence | denotes | Moreover, most of the experiments show that increased ACE2 activity leads to beneficial effects; however, the experiments were usually performed using models in which its “antagonist“ (ACE) pathway was upregulated or ACE2 itself was downregulated, therefore balancing an unbalanced situation. |
T75 | 1390-1449 | Sentence | denotes | What does it happen in models in which the opposite occurs? |
LitCovid-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T16 | 469-480 | Phenotype | denotes | hypotension | http://purl.obolibrary.org/obo/HP_0002615 |
2_test
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
32708755-27082314-20678693 | 642-644 | 27082314 | denotes | 38 |
32708755-29434591-20678694 | 648-650 | 29434591 | denotes | 40 |
32708755-30554115-20678695 | 651-653 | 30554115 | denotes | 41 |
32708755-31427727-20678696 | 654-656 | 31427727 | denotes | 42 |
32708755-20599443-20678697 | 660-662 | 20599443 | denotes | 44 |
32708755-23249272-20678698 | 663-665 | 23249272 | denotes | 45 |